Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

Yuka Tanaka, MD, Takayuki Tabayashi, MD PhD, Yasuyuki Takahashi, MD PhD, Yuta Kimura, MD, Tatsuki Tomikawa, MD PhD, Junichi Watanabe, MD PhD, Tomoe Anan-Nemoto, MD PhD, Morihiko Sagawa, MD PhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, Masahiro Kizaki, MD PhD

Blood (2018) 132 (Supplement 1): 5613.

https://doi.org/10.1182/blood-2018-99-116247

Published: 2018

Journal Articles

The Absolute Count of Lymphocytes Is a Strong Predictive Factor for Relapse/Regrowth Events and Outcomes in Patients with Regressive Methotrexate-Associated Lymphoproliferative Disorders

Michihide Tokuhira, Yuta Kimura, MD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD PhD, Tatsuki Tomikawa, MD PhD, Junichi Watanabe, MD PhD, Tomoe Anan-Nemoto, MD PhD, Morihiko Sagawa, MD PhD, Shuji Momose, MD PhD, Morihiro Higashi, MD PhD, Tabayashi Takayuki, MD PhD, Reiko Nakaseko, MD PhD, Jun-ichi Tamaru, MDPhD, Masahiro Kizaki, MDPhD

Blood (2018) 132 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2018-99-114382

Published: 2018

Journal Articles

Impact of the Duration of Methotrexate Administration and the Specific HLA Alleles on the Regressive Methotrexate-Induced Lymphoproliferative Disorders

Michihide Tokuhira, MD, Shuntaro Saito, MD, Ayumi Okuyama, MD, Katsuya Suzuki, MD, Morihiro Higashi, MD, Shuju Momose, MD, Takayuki Shimizu, MD, Takehiko Mori, MD PhD, Tomoe Anan-Nemoto, MD, Koichi Amano, MD, Shinichiro Okamoto, MD PhD, Tsutomu Takeuchi, MD, Jun-ichi Tamaru, MDPhD, Masahiro Kizaki, MDPhD

Blood (2017) 130 (Supplement 1): 4024.

https://doi.org/10.1182/blood.V130.Suppl_1.4024.4024

Published: 2017

Journal Articles

CD14-CD15+, Possible Cells Are Potent Myeloid-Derived Suppressor Cells, Which Affect the Pathogenesis of Induction and Regression in Methotrexate-Mediated Lymphoproliferative Disorders

Michihide Tokuhira, MD PhD, Shuntaro Saito, MD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Tomoe Anan, MD, PhD, Shuji Momose, MD PhD, Morihiro Higashi, MD, PhD, Takayuki Shimizu, MD PhD, Takehiko Mori, MD PhD, Takayuki Tabayashi, MD PhD, Reiko Watanabe, MD PhD, Jun-ichi Tamaru, MD, PhD, Shinichiro Okamoto, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 2946.

https://doi.org/10.1182/blood.V128.22.2946.2946

Published: 2016

Journal Articles

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Takayuki Tabayashi, MD PhD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Morihiko Sagawa, MD PhD, Tomoe Anan-Nemoto, MDPhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 3256.

https://doi.org/10.1182/blood.V128.22.3256.3256

Published: 2016

Journal Articles

TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways

Morihiko Sagawa, MD, PhD, Tatsuki Tomikawa, MD, Tomoe Anan, MD, Takayuki Tabayashi, MD, PhD, Reiko Watanabe, MD, PhD, Michihide Tokuhira, MD, PhD, Masaki Ri, MD, PhD, Yuichi Hashimoto, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2013) 122 (21): 4427.

https://doi.org/10.1182/blood.V122.21.4427.4427

Published: 2013

Journal Articles

Impact Of Epstein-Barr Viral Infection In The Regression Of Methotrexate-Induced Lymphoproliferative Diseases In Patients With Rheumatoid Arthritis

Tokuhira Michihide, Kimura Yuhta, Takahashi Yasuyuki, Tomikawa Tatsuki, Morihiko Sagawa, Tomoe Anan, Higashi Morihiro, Itoyama Shinji, Tamaru Jun-ichi, Okuyama Ayumi, Amano Koichi, Tabayashi Takayuki, Reiko Watanabe, M.D., Ph.D., Shigehisa Mori, MD, Masahiro Kizaki, MD

Blood (2013) 122 (21): 3006.

https://doi.org/10.1182/blood.V122.21.3006.3006

Published: 2013

NARROW

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

The Absolute Count of Lymphocytes Is a Strong Predictive Factor for Relapse/Regrowth Events and Outcomes in Patients with Regressive Methotrexate-Associated Lymphoproliferative Disorders

Impact of the Duration of Methotrexate Administration and the Specific HLA Alleles on the Regressive Methotrexate-Induced Lymphoproliferative Disorders

CD14-CD15+, Possible Cells Are Potent Myeloid-Derived Suppressor Cells, Which Affect the Pathogenesis of Induction and Regression in Methotrexate-Mediated Lymphoproliferative Disorders

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways

Impact Of Epstein-Barr Viral Infection In The Regression Of Methotrexate-Induced Lymphoproliferative Diseases In Patients With Rheumatoid Arthritis

Email alerts

ASH Publications

American Society of Hematology

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

The Absolute Count of Lymphocytes Is a Strong Predictive Factor for Relapse/Regrowth Events and Outcomes in Patients with Regressive Methotrexate-Associated Lymphoproliferative Disorders

Impact of the Duration of Methotrexate Administration and the Specific HLA Alleles on the Regressive Methotrexate-Induced Lymphoproliferative Disorders

CD14-CD15+, Possible Cells Are Potent Myeloid-Derived Suppressor Cells, Which Affect the Pathogenesis of Induction and Regression in Methotrexate-Mediated Lymphoproliferative Disorders

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways

Impact Of Epstein-Barr Viral Infection In The Regression Of Methotrexate-Induced Lymphoproliferative Diseases In Patients With Rheumatoid Arthritis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only